Richard Channick
Overview
Explore the profile of Richard Channick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
1648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasuski R, Tobore T, Studer S, Jansa P, Sitbon O, Hoeper M, et al.
JACC Adv
. 2025 Feb;
4(3):101626.
PMID: 39999520
Background: Pulmonary arterial hypertension (PAH) is a common complication among patients with congenital heart disease (CHD). Despite advances in PAH treatment, evidence for the benefits of PAH therapies in CHD-PAH...
2.
Saggar R, Brownstein A, Channick R
Eur Respir J
. 2024 Dec;
64(6).
PMID: 39736110
No abstract available.
3.
Bravo-Jaimes K, Venkatesh P, Lluri G, Reardon L, Cruz D, Vucicevic D, et al.
Int J Cardiol Congenit Heart Dis
. 2024 Dec;
8:100361.
PMID: 39712065
No abstract available.
4.
Chin K, Channick R, Kim N, Ong R, Turricchia S, Martin N, et al.
Cardiol Ther
. 2024 Nov;
13(4):775-796.
PMID: 39585521
Introduction: Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) are scarce. The OPUS/OrPHeUS studies enrolled patients with PAH...
5.
Flynn S, Chen H, Kerbel R, Gupta S, Jasuja S, Saggar R, et al.
BMC Pulm Med
. 2024 Oct;
24(1):538.
PMID: 39468558
Background: Sepsis is a common cause of death in patients with pulmonary arterial hypertension (PAH). Treatment requires careful fluid management and hemodynamic support. This study compares patients with or without...
6.
Mounsey L, Alape Moya D, Wright C, Langer N, Stone J, Channick R, et al.
Chest
. 2024 Oct;
PMID: 39454997
Background: Pulmonary endarterectomy (PEA) is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH). Although most have normalization of pulmonary artery (PA) pressures, development of residual pulmonary hypertension (RPH)...
7.
Kim N, Channick R, Delcroix M, Madani M, Pepke-Zaba J, Borissoff J, et al.
Eur Respir J
. 2024 Sep;
64(4).
PMID: 39326918
Background: SELECT was the first global randomised controlled trial of selexipag with standard of care in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. Methods: SELECT was a multicentre,...
8.
Chin K, Channick R, Kim N, MacDonald G, Ong R, Martin N, et al.
Adv Ther
. 2024 Sep;
41(11):4205-4227.
PMID: 39316293
Introduction: Historically, patients recently (≤ 6 months) diagnosed with pulmonary arterial hypertension (PAH; incident) have had poorer survival than those with a longer (> 6 months) time from PAH diagnosis...
9.
Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E, et al.
Eur Respir J
. 2024 Aug;
64(4).
PMID: 39209469
Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common and underrecognised. The presence of PH in the setting of lung disease has been consistently shown to be...
10.
Hong J, Medzikovic L, Sun W, Wong B, Ruffenach G, Rhodes C, et al.
Circulation
. 2024 Aug;
150(16):1268-1287.
PMID: 39167456
Background: Integrative multiomics can elucidate pulmonary arterial hypertension (PAH) pathobiology, but procuring human PAH lung samples is rare. Methods: We leveraged transcriptomic profiling and deep phenotyping of the largest multicenter...